ERBB2 and breast carcinoma: And MAGEA3 is reported to up-regulate the expression of survivin in P53-dependent and independent ways, and the latter one induced chemotherapy resistance, endocrinal therapy failure, and her2-target therapy tolerance in breast cancer [26–28].